Penserra Capital Management LLC Allovir, Inc. Transaction History

Penserra Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$12.94 - $25.99 $19,215 - $38,595	-1,485 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $84 - $125	5 Added 0.34%	1,485 $37,000
Q2 2021 Aug 12, 2021	BUY	$19.44 - $25.06 $194 - $250	10 Added 0.68%	1,480 $29,000
Q1 2021 May 13, 2021	SELL	$20.81 - $45.5 $520 - $1,137	-25 Reduced 1.67%	1,470 $34,000
Q4 2020 Feb 12, 2021	BUY	$23.94 - $46.81 $35,790 - $69,980	1,495 New	1,495 $57,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.